Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

These findings will be presented at the American Association for Cancer Research Special Conference in Cancer Research: Liquid Biopsy from November 13-16, 2024, in San Diego, Calif. A new study ...

Matthias Löhr and colleagues provide an in-depth review of diagnostic methods for pancreatic incidentaloma—incidental ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

As part of the deal, providers will have access to Tempus' tests such as the xT solid tumor and normal match DNA sequencing test, xR whole-transcriptome sequencing RNA test, liquid biopsy-based xF/xF+ ...

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic ...

The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour ...

In recent research published in eGastroenterology, Dr. J-Matthias Löhr and colleagues provide an in-depth review of ...

In recent research published in eGastroenterology, Dr. J-Matthias Löhr and colleagues provide an in-depth review of ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia has entered a five-year partnership with the ...

Q3 2024 Earnings Call Transcript November 6, 2024 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.74. Operator: Hello, everyone, and welcome to the ...

Results of a study recently published in the journal JCO Precision Oncology show that in the clinical trial context, combined ...